Valerie Pierce - Mar 2, 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Signature
/s/ Valerie Pierce
Stock symbol
NGM
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 04:03 PM
Previous filing
Mar 4, 2022
Next filing
Nov 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Award $0 +49K +734.96% $0.00 55.7K Mar 2, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +147K $0.00 147K Mar 2, 2023 Common Stock 147K $4.36 Direct F3
transaction NGM Stock Option (Right to Buy) Award $0 +150K $0.00 150K Mar 2, 2023 Common Stock 150K $4.36 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2 Includes 1,805 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on May 14, 2021 and 1,252 ESPP shares acquired on May 13, 2022.
F3 The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F4 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.